Drug intelligence / Profile preview

CHF 5188

Development stage: Unknown
Lead developer: Chiesi
Modality: Small Molecules
Administration: Inhalation

Overview

CHF 5188 is an investigational drug that was studied for its bronchodilator effects in patients with moderate or severe asthma. It was evaluated in a clinical trial to determine whether once-daily morning dosing could maintain bronchodilation in this patient population. The specific mechanism of action, molecular target, and chemical class of CHF 5188 are not detailed in the available public sources. The developer associated with this code name is Chiesi Farmaceutici, as indicated by the "CHF" prefix commonly used for their pipeline compounds.

Beyond the preview

Go deeper on CHF 5188.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHF 5188.

Explore the full profile